Liquidia Corporation

NasdaqCM LQDA

Liquidia Corporation Current Liabilities for the quarter ending September 30, 2024: USD 33.84 M

Liquidia Corporation Current Liabilities is USD 33.84 M for the quarter ending September 30, 2024, a 178.36% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Liquidia Corporation Current Liabilities for the quarter ending September 30, 2023 was USD 12.16 M, a 62.95% change year over year.
Liquidia Corporation Current Liabilities for the quarter ending September 30, 2022 was USD 7.46 M, a 5.60% change year over year.
Liquidia Corporation Current Liabilities for the quarter ending September 30, 2021 was USD 7.06 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	145
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Tobacco

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key trends

Past 5 years